Innocan’s SHIR (TM) Beauty & Science CBD Derma Cosmetics Products Passed Safety Assessments and Have Been Approved for Marketing in the European Union

Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – August 6, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that its SHIR™ CBD Derma Cosmetic product line, has successfully passed safety assessment in accordance with European Union (EU) cosmetic regulation No 1223/2009 and received a EU Cosmetic ProductContinue reading “Innocan’s SHIR (TM) Beauty & Science CBD Derma Cosmetics Products Passed Safety Assessments and Have Been Approved for Marketing in the European Union”

Innocan’s Over-The-Counter Pain Relief Spray Receives FDA’s Technical Validation for Marketing in the USA

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce that it has received notice from the FDA that Innocan’s over-the-counter Relief & Go Pain Relief spray product has successfully received technical validation and approval to commence marketing in the USA. Innocan’s pain relief formulation contains a combination of MagnesiumContinue reading “Innocan’s Over-The-Counter Pain Relief Spray Receives FDA’s Technical Validation for Marketing in the USA”

InnoCan Pharma Collaborate with Recipharm on its CBD Loaded Exosome (CLX) Treatments

InnoCan Pharma Corporation (CNSX: INNO) (FSE: IP4), is pleased to announce its collaboration with Recipharm, Israel to synthesize and analyze cannabinoid loaded exosomes. Recipharm unites more than 30 facilities across 10 different countries offering a range of services, mainly in two different operating areas, pharmaceutical development services and manufacturing services. Recipharm offers seamless tech transfer from RecipharmContinue reading “InnoCan Pharma Collaborate with Recipharm on its CBD Loaded Exosome (CLX) Treatments”

Innocan Pharma’s Corporate Update

Calgary, Alberta–(Newsfile Corp. – July 2, 2020) – Innocan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the “Company” or “Innocan“) announced today that Mr. Bill Macdonald has resigned as a member of the Company’s board of directors effective June 29, 2020. The Company wishes to thank Mr. Macdonald for all his efforts and supporting the CompanyContinue reading “Innocan Pharma’s Corporate Update”

InnoCan Pharma Announces the Successful Completion of an Independent Clinical Study Demonstrating Safety and Skin Tolerance of Its CBD Derma Cosmetic Line

Herzeliya, Israel and Calgary, Alberta–(Newsfile Corp. – June 26, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce the results from the first Dermal clinical study of Relief & Go ™ and Shir ™ product lines. The double blinded randomized controlled study assessed the tolerance degree ofContinue reading “InnoCan Pharma Announces the Successful Completion of an Independent Clinical Study Demonstrating Safety and Skin Tolerance of Its CBD Derma Cosmetic Line”

Innocan Pharma Announces Mackie Research’s Institutional Sales Group Issues Enterprise Publication on the Company

Innocan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce that Mackie Research Capital Corporation’s institutional sales group has issued an Enterprise publication on the Company. The Enterprise publication provides valuable insight into companies that embody value-add for investors, have distinguished themselves among their peers and are bringing innovative andContinue reading “Innocan Pharma Announces Mackie Research’s Institutional Sales Group Issues Enterprise Publication on the Company”

Water Ways Announces TSX Venture Exchange Conditional Approval for Warrant Repricing of Certain Warrants to $0.06

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, June 16, 2020 (GLOBE NEWSWIRE) — Water Ways Technologies Inc. (TSXV: WWT) (“Water Ways” or the “Company“) wishes to announce that, it has received conditional TSXV Venture Exchange (the “Exchange”) approval to amend (the “Amendment”) the exercise price (the “Exercise Price”) of the followingContinue reading “Water Ways Announces TSX Venture Exchange Conditional Approval for Warrant Repricing of Certain Warrants to $0.06”

Naturally Splendid – Exciting Times

These are exciting times to be a Naturally Splendid Enterprises Ltd. (“NSE”) shareholder. With the closing of NSE private placement and the Phase II clinical trials for a potential Covid-19 treatment being fast-tracked by Health Canada for Cavaltinibtm, there certainly appear to be bright days ahead. Covid-19 Naturally Splendid has partnered with Biologic Pharmamedical ResearchContinue reading “Naturally Splendid – Exciting Times”

Canada House Wellness Group Announces Agreement With the Société Québécoise Du Cannabis and Receives Follow on Purchase Order From Western Province

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATESCANADA HOUSE WELLNESS GROUP ANNOUNCES AGREEMENT WITH THE SOCIÉTÉ QUÉBÉCOISE DU CANNABIS AND RECEIVES FOLLOW ON PURCHASE ORDER FROM WESTERN PROVINCEToronto – June 11, 2020 (CNW) – Canada House Wellness Group Inc. (CSE: CHV) (“Canada House” or the “Company”), a fully integrated medicalContinue reading “Canada House Wellness Group Announces Agreement With the Société Québécoise Du Cannabis and Receives Follow on Purchase Order From Western Province”